3 documents found, page 1 of 1
Use of putative hepatoprotective agents as an adjunct to anti-TB treatment in E...
Kirakosyan, O; Reimann, M; Andersen, AB; Bjarnason, A; Bakos, Á; Dyrhol-Riise, AM; McLaughlin, AM; Nita, C; Pieridou, D; Chesov, D; Davidavičienė, EV"Background: Anecdotal information suggests that clinical practice regarding the use of putative hepatoprotective agents in TB treatment varies across countries in the WHO European Region. Methods: Between November 2023 and May 2024, we conducted a standardised questionnaire survey on the use of putative hepatoprotective agents in patients receiving TB treatment among Tuberculosis Network European Trials Group ...
Tuberculosis incidence in foreign-born people residing in European countries in...
Vasiliu, A; Köhler, N; Altpeter, E; Ægisdóttir, TR; Amerali, M; de Oñate, WA; Bakos, Á; D'Amato, S; Cirillo, DM; van Crevel, R; Davidaviciene, E"Background European-specific policies for tuberculosis (TB) elimination require identification of key populations that benefit from TB screening. Aim We aimed to identify groups of foreign-born individuals residing in European countries that benefit most from targeted TB prevention screening. Methods The Tuberculosis Network European Trials group collected, by cross-sectional survey, numbers of foreign-born TB...
Rifapentine access in Europe: growing concerns over key tuberculosis treatment ...
Guglielmetti, L; Günther, G; Leu, C; Cirillo, D; Duarte, R; Garcia-Basteiro, AL; Goletti, D; Jankovic, M; Kuksa, L; Maurer, FP; Méchaï, F; Tiberi, S[No abstract available]